TherapeuticsMD, Inc. Earnings Per Share Disclosure
11. Loss per common share
The following table sets forth the computation of basic and diluted (loss) income per common share for the periods presented (in thousands, except per share amounts):
| Years Ending December 31, | ||||||||
| 2025 | 2024 | |||||||
| Numerator: | ||||||||
| Net loss from continuing operations | $ | (653 | ) | $ | (2,312 | ) | ||
| Income from discontinued operations | 84 | 131 | ||||||
| Net loss | $ | (569 | ) | $ | (2,181 | ) | ||
| Denominator: | ||||||||
| Weighted average common shares outstanding - basic | 11,569 | 11,532 | ||||||
| Effect of dilutive securities | ||||||||
| Weighted average common shares outstanding - diluted | 11,569 | 11,532 | ||||||
| Loss per common share, continuing operations | ||||||||
| Basic | $ | (0.06 | ) | $ | (0.20 | ) | ||
| Diluted | $ | (0.06 | ) | $ | (0.20 | ) | ||
| Income per common share, discontinued operations | ||||||||
| Basic | $ | 0.01 | $ | 0.01 | ||||
| Diluted | $ | 0.01 | $ | 0.01 | ||||
Since we reported a net loss from continuing operations for the years ending December 21, 2025 and 2024, our potentially dilutive securities are deemed to be anti-dilutive, accordingly, there was no effect of dilutive securities. Therefore, our basic and diluted loss per common share and our basic and diluted weighted average common shares are the same for the years ending December 21, 2025 and 2024, respectively.
The following table sets forth the outstanding securities as of the periods presented which were not included in the calculation of diluted earnings per common share during 2025 and 2024 (in thousands):
| December 31, | ||||||||
| 2025 | 2024 | |||||||
| Stock options | 105 | 57 | ||||||
| RSUs | 26 | 2 | ||||||
| PSUs | 5 | |||||||
| Warrants | 98 | 98 | ||||||
| 229 | 162 | |||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 30, 2026 | Showing above |
| 2024 | Mar 27, 2025 | |
| 2023 | Mar 29, 2024 | |
| 2022 | Apr 7, 2023 | |
| 2021 | Mar 23, 2022 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.